Accepted for Publication: August 12, 2013.
Published Online: November 11, 2013. doi:10.1001/jamaneurol.2013.4749.
Study concept and design: Kefalopoulou, Piccini, Quinn, Foltynie.
Acquisition of data: Kefalopoulou, Politis, Mencacci, Bhatia, Jahanshahi, Widner, Rehncrona, Brundin, Björklund, Lindvall, Limousin, Quinn, Foltynie.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Kefalopoulou.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kefalopoulou, Brundin.
Study supervision: Quinn, Foltynie.
Conflict of Interest Disclosures: Dr Brundin owns shares in the company Parkcell AB, which aims to develop a transplantation therapy for PD by using skin-derived cells. No other disclosures were reported.
Funding/Support: This work was supported in part by the European Commission under the Seventh Framework Programme, HEALTH, Collaborative Project TRANSEURO (contract 242003) (www.transeuro.org.uk) and by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium, whose members are from the UCL Institute of Neurology, the University of Sheffield, and the MRC Protein Phosphorylation Unit at the University of Dundee. The original grafting was part funded by the UK Parkinson’s Disease Society (now Parkinson’s UK).
Role of the Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Other physicians and nurses at Queen Square involved in long-term clinical follow-up and assessments of these 2 patients include Gregor Wenning, MD, PhD, Anette Schrag, MD, PhD, and Lesley Crabb (now Swinn).